Navigation Links
Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
Date:5/30/2008

IRVINE, Calif., May 30 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, said today that it has received additional questions from the U.S. Food and Drug Administration (FDA) regarding the company's submission for premarket approval of LifeStent products for a superficial femoral artery (SFA) indication. These questions pertain to preclinical bench testing and the clarification of open items already under review by the FDA. Edwards expects to respond promptly to the FDA and continues to anticipate receiving an SFA indication by the end of the year. Earlier this year, Edwards completed the sale of the LifeStent product line to C.R. Bard, Inc.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, the company's ability to promptly respond to the FDA's questions and receive an SFA indication by the end of the year. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2007.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna, and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Aflac to be Primary Sponsor of Carl Edwards and the No. 99 Ford Fusion
2. Edwards Lifesciences Announces Retirement of Director Vernon Loucks
3. Edwards Lifesciences to Host Earnings Conference Call on April 22, 2008
4. Optimal Readings Appoints Operations Veteran Rita Edwards as SVP Clinical Operations
5. Edwards Lifesciences Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan
6. Edwards Lifesciences to Present at the Citi 5th Annual Small and Mid-Cap Conference
7. Edwards Lifesciences to Present at the Cowen and Company Annual Healthcare Conference
8. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
9. Edwards Lifesciences Reports Strong Fourth Quarter Sales
10. Edwards Lifesciences Completes Sale of LifeStent Product Line to Bard
11. Edwards Lifesciences to Present at the Southern California Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:12/6/2016)... Georgia (PRWEB) , ... December 06, 2016 , ... ... consecutive year to "Training" magazine’s 2017 Training Top 125 for their industry leading ... This prestigious, annual award recognizes USA as among the global elite in employer-sponsored ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, ... today on its R&D program in the use ... pulmonary disease (COPD). In June, 2015 InMed initiated ... to identify the targets and potential active compounds ... COPD. Subsequently, with in vitro assays using human ...
(Date:12/5/2016)... WARSAW, Ind. , Dec. 5, 2016  Zimmer ... "Company") today announced that, pursuant to its previously-announced ... securities identified in the table below (collectively, the ... Notes were validly tendered and not validly withdrawn ... York City time, today, December 5, ...
(Date:12/5/2016)... 5, 2016 Sangamo BioSciences, Inc. (Nasdaq: ... presentation of preclinical and manufacturing data that support SB-525, its ... Annual Meeting of the American Society of Hematology (ASH) ... from December 3-6, 2016. "We have developed an ... we believe is highly competitive, and we remain on track ...
Breaking Medicine Technology: